Nykredit Realkredit A/S
To the Nasdaq Copenhagen A/S
2 March 2021
New Final Bond Terms for Nykredit Realkredit A/S's Base Prospectus dated 13 May 2020
Nykredit issues new fixed rate bonds (SDO) with maturity date 1 October 2053, interest-only period up to 30 years and a coupon of 1.5%.
In connection with the opening of new ISINs under Nykredit Realkredit A/S's Base Prospectus dated 13 May 2020 with amendments, Nykredit issues new Final Bond Terms.
The Final Bond Terms for series 01E are stated below.
Nykredit Realkredit A/S's Base Prospectus dated 13 May 2020 and the relevant Final Bond Terms are available for download in Danish and English. In the event of discrepancies between the original Danish text and the English translation, the Danish text shall prevail. The documents can be found on Nykredit's website at nykredit.com/ir.
| ISIN | Capital centre | Currency | Coupon | Loan repayment profile | Maturity |
| DK0009532020 | E (SDO) | DKK | 1.50 % | Hybrid (up to 30-year interest-only period) | 01.10.2053 |
Questions may be addressed to Group Treasury, Lars Mossing Madsen, tel +45 44 55 11 66, or Christian Mauritzen, tel +45 44 55 10 14.
Attachment
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
ALK Abello19.12.2025 22:46:46 CET | Press release
Major shareholder announcement
ALK Abello19.12.2025 22:46:46 CET | Pressemeddelelse
Storaktionærmeddelelse
Zealand Pharma19.12.2025 22:00:00 CET | Press release
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
Boehringer Ingelheim Limited19.12.2025 21:10:00 CET | Press release
U.S. FDA approves JASCAYD® (nerandomilast) tablets for the treatment of progressive pulmonary fibrosis in adults
Novartis Pharma AG19.12.2025 20:30:06 CET | Press release
Novartis and US government reach agreement on lowering drug prices in the US
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
